- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Hyperintensity.
Displaying page 1 of 1.
| EudraCT Number: 2019-004733-17 | Sponsor Protocol Number: XAMNPEAP2019 | Start Date*: 2020-02-25 | |||||||||||
| Sponsor Name:Aurora Pujol Onofre | |||||||||||||
| Full Title: Effect of plasma exchange by albumin replacement in Adrenomyeloneuropathy: unicentric, single arm, proof of concept trial | |||||||||||||
| Medical condition: Adrenomyeloneuropathy | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-003209-14 | Sponsor Protocol Number: 5815 | Start Date*: 2014-09-01 |
| Sponsor Name:Hôpitaux Universitaires de Strasbourg | ||
| Full Title: ASSESSMENT OF EARLY CHANGES OBSERVABLE IN DIFFUSION MRI IN RESPONSE TO TYSABRI TREATMENT TO TWO YEARS IN PATIENTS WITH MULTIPLE SCLEROSIS | ||
| Medical condition: MULTIPLE SCLEROSIS | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-003505-26 | Sponsor Protocol Number: TOHNER/31 | Start Date*: 2019-03-18 | |||||||||||
| Sponsor Name:ABIOGEN PHARMA S.P.A. | |||||||||||||
| Full Title: Randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of treatment with Neridronate 100 mg (4 infusions over a period of 10 days) in patients with tra... | |||||||||||||
| Medical condition: Transient osteoporosis of the hip. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-005906-32 | Sponsor Protocol Number: WAKE-UP | Start Date*: 2012-09-24 | |||||||||||
| Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
| Full Title: Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial | |||||||||||||
| Medical condition: Patients with acute ischemic stroke proven by MRI and unknown time from symptom onset which otherwise fulfil the approval criteria for intravenous thrombolysis in acute stroke | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) BE (Completed) GB (Completed) DK (Completed) ES (Completed) NL (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-004766-26 | Sponsor Protocol Number: NL58747 | Start Date*: 2017-03-08 |
| Sponsor Name:Academic Medical Center | ||
| Full Title: Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies (IMMEDIATE): a pilot study. | ||
| Medical condition: idiopathic inflammatory myopathies | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-004505-16 | Sponsor Protocol Number: CONVINCE | Start Date*: 2016-08-08 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:University College Dublin | ||||||||||||||||||||||||||||||||||||||
| Full Title: CONVINCE - (COlchicine for preventioN of Vascular Inflammation in Non- CardioEmbolic stroke) – a randomised clinical trial of low-dose colchicine for secondary prevention after stroke | ||||||||||||||||||||||||||||||||||||||
| Medical condition: The prevention of recurrent stroke and coronary events (fatal and non- fatal) after ischaemic stroke and transient ischaemic attack (TIA) not caused by cardiac embolism or other causes unrelated to... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: IE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) DK (Completed) PT (Completed) BE (Completed) LT (Completed) NL (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-001557-26 | Sponsor Protocol Number: CV185-048 | Start Date*: 2008-04-29 | |||||||||||
| Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
| Full Title: Apixaban Versus Acetylsalicyclic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double Blind Trial ... | |||||||||||||
| Medical condition: Patients with atrial fibrillation and at least one additional risk factor for stroke who have failed or are unsuitable for vitamin K antagonist therapy. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) FR (Completed) SE (Completed) BE (Completed) DE (Completed) FI (Completed) ES (Completed) DK (Completed) CZ (Completed) AT (Completed) GR (Completed) PL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-004130-25 | Sponsor Protocol Number: DUR001-304 | Start Date*: 2016-03-07 |
| Sponsor Name:Durata Therapeutic International B.V. | ||
| Full Title: A phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Hematogenous Osteom... | ||
| Medical condition: Acute Hematogenous Osteomyelitis of the Long Bones Known or Suspected to be due to Gram-Positive Organisms | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: ES (Prematurely Ended) FR (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-000089-45 | Sponsor Protocol Number: OT-15-001 | Start Date*: 2016-11-07 | |||||||||||
| Sponsor Name:Orbus Therapeutics, Inc. | |||||||||||||
| Full Title: A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur Af... | |||||||||||||
| Medical condition: Anaplastic Astrocytoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) NL (Completed) FR (Completed) IT (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-002818-12 | Sponsor Protocol Number: ICH02 | Start Date*: 2014-06-13 | |||||||||||
| Sponsor Name:The John Hopkins University | |||||||||||||
| Full Title: A phase III, randomized, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral haemorrhage. | |||||||||||||
| Medical condition: Spontaneous supratentorial intracerebral haemorrhage | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) HU (Completed) ES (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.